FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer–subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306
Sebastian Stintzing(University of Southern California), Volker Heinemann(Comprehensive Cancer Center Vienna), Claude Stoll, Ursula Vehling‐Kaiser(University of Applied Sciences Landshut), Dominik Paul Modest, Elke Jäger(Krankenhaus Nordwest), Andreas Jung(German Cancer Research Center), Tobias Heintges(Lukaskrankenhaus), Jens Neumann(Ludwig-Maximilians-Universität München), Clemens Gießen, Ludwig Fischer von Weikersthal(Klinikum St. Marien Amberg), Thomas Kirchner(Friedrich-Alexander-Universität Erlangen-Nürnberg), Werner Scheithauer(Comprehensive Cancer Center Vienna), Thomas Decker
Cited by 110
Related Papers
Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial
|The Lancet|2008|1.9k
FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2014|1.7k